Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > S(-)-RACLOPRIDE L-TARTRATE

S(-)-RACLOPRIDE L-TARTRATE

S(-)-RACLOPRIDE L-TARTRATE structure

S(-)-RACLOPRIDE L-TARTRATE 

structure
  • CAS No:

    84225-95-6

  • Formula:

    C15H20Cl2N2O3

  • Chemical Name:

    S(-)-RACLOPRIDE L-TARTRATE

  • Synonyms:

    (S)-3,5-dichloro-N-((1-ethylpyrrolidin -2-yl)methyl)-2-hydroxy-6- methoxybenzamide (2R,3R) -2,3-dihydroxysuccinate;(2S)-3,5-DICHLORO-N-[(1-ETHYL-2-PYRROLIDINYL)-METHYL]-6- METHOXYSALICYLAMIDE;BENZAMIDE, 3,5-DICHLORO-N-[[(2S)-1-ETHYL-2-PYRROLIDINYL]METHYL]-2-HYDROXY-6-METHOXY-;3,5-Dichloro-N-[(2S)-1-ethyl-2-pyrrolidinyl]-2-hydroxy-6-methoxybenzamide;FLA-870;RAC;3,5-Dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-methoxy-6-hydroxybenzamide;3,5-Dichloro-N-[[(2S)-1-ethylpyrrolidine-2α-yl]methyl]2-hydroxy-6-methoxybenzamide

Description

3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide is a member of salicylamides.|Raclopride has been used in trials studying Parkinson Disease.|A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.


Raclopride is a selective dopamine D2/D3receptor antagonist with Kivalues of 1.8, 3.5, 2,400, and 18,000 nM for D2, D3, D4, and D1receptors, respectively. It passes the blood brain barrier and can be used inin vivobinding and autoradiography studies of the dopamine system under normal and pathological conditions such as Huntington’s disease.


Yellowish solid


ChEBI: 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide is a member of salicylamides.

S(-)-RACLOPRIDE L-TARTRATE Basic Attributes

347.24

347.24

430K3SOZ7G

DTXSID9045687

white

2933.99.8290

Characteristics

61.8 Ų

1.288±0.06 g/cm3(Predicted)

52.0 to 56.0 °C

420.3±45.0 °C(Predicted)

5.93±0.50(Predicted)

Keep in dark place,Sealed in dry,2-8°C

Safety Information

3

22-24/25

CV3465000

Store at -20°C

Drug Information

Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)|Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)

C11, Raclopride

S(-)-RACLOPRIDE L-TARTRATE Use and Manufacturing

neuroleptic;selective dopamine D1/D2 receptors antagonist


A labelled dopamine receptor


Raclopride is a potent D2DR/D3DR antagonist.

Computed Properties

Molecular Weight:347.2
XLogP3:2.9
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:5
Exact Mass:346.0850979
Monoisotopic Mass:346.0850979
Topological Polar Surface Area:61.8
Heavy Atom Count:22
Complexity:386
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.